Skip to main content

Table 2 The relationship between treatment outcome and proteinuria before RTX administration and renal pathology in pediatric patients with NS

From: Efficacy of rituximab therapy in children with nephrotic syndrome: a 10-year experience from an Iranian pediatric hospital

NS type Proteinuria before RTX treatment Outcome Total
Complete remission No response Partial remission
SDNS (p = 0.145) Nephrotic 5 (38.5%) 0 (0.0%) 0 (0.0%) 5 (19.2%)
Sub-nephrotic 4 (30.8%) 2 (50.0%) 6 (66.7%) 12 (46.2%)
Physiologic 4 (30.8%) 2 (50.0%) 3 (33.3%) 9 (34.6%)
Total   13 (100%) 4 (100%) 9 (100%) 26 (100%)
SRNS (p = 0.005) Nephrotic 1 (20.0%) 0 (0.0%) 0 (0.0%) 1 (4.5%)
Sub-nephrotic 0 (0.0%) 0 (0.0%) 6 (66.7%) 6 (27.3%)
Physiologic 4 (80.0%) 8 (100%) 3 (33.3%) 15 (68.2%)
Total   5 (100%) 8 (100%) 9 (100%) 22 (100%)
SDNS+SRNS (p = 0.001) Nephrotic 6 (33.3%) 0 (0.0%) 0 (0.0%) 6 (12.5%)
Sub-nephrotic 4 (22.2%) 2 (16.7%) 12 (66.7%) 18 (37.5%)
Physiologic 8 (44.4%) 10 (83.3%) 6 (33.3%) 24 (50.0%)
Total   18 (100%) 12 (100%) 18 (100%) 48 (100%)
NS type Renal pathologya Outcome Total
Complete remission No response Partial remission
SDNS (p = 0.113) MCNS 3 (23.1%) 1 (25.0%) 0 (0.0%) 4 (15.4%)
DMP 9 (69.2%) 1 (25.0%) 8 (88.9%) 18 (69.2%)
FSGS 1 (7.7%) 2 (50.0%) 1 (11.1%) 4 (15.4%)
MGN 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Total   13 (100%) 4 (100%) 9 (100%) 26 (100%)
SRNS (p = 0.047) MCNS 1 (20.0%) 0 (0.0%) 0 (0.0%) 1 (4.5%)
DMP 1 (20.0%) 1 (12.5%) 7 (77.8%) 9 (40.9%)
FSGS 3 (60.0%) 6 (75.0%) 2 (22.2%) 11 (50.0%)
MGN 0 (0.0%) 1 (12.5%) 0 (0.0%) 1 (4.5%)
Total   5 (100%) 8 (100%) 9 (100%) 22 (100%)
SDNS+SRNS (p = 0.003) MCNS 4 (22.2%) 1 (8.3%) 0 (0.0%) 5 (10.4%)
DMP 10 (55.6%) 2 (16.7%) 15 (83.3%) 27 (56.2%)
FSGS 4 (22.2%) 8 (66.7%) 3 (16.7%) 15 (31.2%)
MGN 0 (0.0%) 1 (8.3%) 0 (0.0%) 1 (2.1%)
Total   18 (100%) 12 (100%) 18 (100%) 48 (100%)
  1. aMCNS Minimal change nephrotic syndrome, FSGS Focal and segmental glomerulosclerosis, DMP Diffuse mesangial proliferation, MGN Membranous glomerulonephritis